TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03335254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
Study: NCT01087151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study: NCT03942107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: single-visit RCT
Description: both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
Study: NCT03335254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
Study: NCT02580513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Misalignment
Study: NCT00587847

Intervention type: DRUG
Group type: OTHER
Intervention: Campath
Description: Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
Study: NCT00784680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily
Study: NCT00343382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pilocarpine hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pilocarpine hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02601547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-FDG brain imaging and NPT
Description: PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
Study: NCT04032080

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug 1: LY3023414; Drug 2: Prexasertib
Description: Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses.
Study: NCT00000572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: positive-pressure ventilation
Description: Detailed computer protocol controlled positive pressure ventilation
Study: NCT00784680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily
Study: NCT02068222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study: NCT02380664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (Powerplate®)
Description: Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumping intervention
Description: Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
Study: NCT03942107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: two-visit RCT
Description: after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
Study: NCT03995394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Reinforcement Text Message
Description: A text message comprising the words, Great job! We're so proud of you! Keep up the good work!
Study: NCT02168855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active nicotine gum
Description: 2 mg, standard over-the-counter nicotine replacement therapy gum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral therapy
Description: Standard behavioral therapy for smoking cessation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard behavioral therapy
Description: Standard behavioral therapy for smoking cessation
Study: NCT04490694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Intervention Description：lenvatinib will be administered daily (for patients \<60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
Study: NCT02991573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prime & Bond Universal
Description: Prime \& Bond Universal
Study: NCT01237665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXO regimen
Description: IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22.
Study: NCT00705627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy plus concurrent chemoradiotherapy
Description: Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
Study: NCT03500315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV D+/R+
Description: Kidney from an HIV-infected deceased donor
Study: NCT04912297

Intervention type: BIOLOGICAL
Intervention: 10-valent pneumococcal conjugate vaccine, PCV10
Description: 10-valent pneumococcal conjugate vaccine, PCV10
Study: NCT02759393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: receiving 8-week PPI
Study: NCT00000572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal membrane oxygenation (CO2 removal)
Description: Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
Study: NCT04123223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer Games
Description: Sham placebo treatment
Study: NCT01009190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-01367338
Description: Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
Study: NCT02759393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: receiving 8-week PPI
Study: NCT01009190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard doses of intravenous Carboplatin administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-01367338
Description: RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
Study: NCT04149652

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Elastosonography
Description: Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Elastosonography
Description: Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Elastosonography
Description: Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
Study: NCT03957525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Operative Preparatory Virtual Reality Program
Description: The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Operative Preparatory Virtual Reality Program
Description: The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Operative Preparatory Virtual Reality Program
Description: The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery
Study: NCT03736031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (Promotora)
Description: If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
Study: NCT04914169

Intervention type: DEVICE
Intervention: ICRS
Description: The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
Study: NCT03100123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin 81 mg po daily in tablet form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
Study: NCT02054689

Intervention type: RADIATION
Group type: OTHER
Intervention: Fractionated Stereotactic Radiosurgery
Description: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
Study: NCT02991573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prime & Bond Universal
Description: Prime \& Bond Universal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ceram X
Study: NCT01137071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody Hu3S193
Description: 30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation.
Study: NCT01009190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard doses of intravenous Carboplatin administered every 3 weeks
Study: NCT01443832

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fe57 and Fe58-FeSO4 stable isotopes
Description: \[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
Study: NCT01808885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olesoxime (TRO19622)
Description: olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule shells with identical appearance as the active compound TRO19622
Study: NCT03928626

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regulation of craving
Description: Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (NO REGULATION)
Description: In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
Study: NCT02599623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
Study: NCT01498718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
Study: NCT00718341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AF056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01325714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAVeD Intervention
Description: In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain.
Study: NCT04371341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block by 0.25% bupivacaine
Description: A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block by 0.25% bupivacaine
Description: A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block by 0.25% bupivacaine
Description: A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.